Solution Study
Monday, October 06
12:25 PM - 12:50 PM
Live in Berlin
Less Details
On average innovative pharmaceuticals have immensely benefited the world as seen by increasing life expectancy globally and reduction of mortality and morbidity in a host of infectious diseases and so on. At the same time, endemic issues like T2D, hypertension, fatty liver consistently increased despite the availability of innovative drugs since the last 25 years. This value leakage results in lost revenue for Pharma along with higher GDP spend on population health (due to exacerbations/hospitalizations). As an example, the state of HbA1c has deteriorated in most of the world despite the steady stream of availability of highly effective drugs since 2005. There are several reasons for this paradox. In this session you will learn more about:
Aditya is a seasoned healthcare strategy consultant with over 20 years of experience helping pharmaceutical and medical device companies navigate complex challenges—from early-stage development to successful commercialization. His expertise spans multiple therapeutic areas, including CVRM, oncology, immunology, and respiratory diseases. Aditya has a strong track record in bridging science and strategy, working across disease and product levels. He supports clients with partnering strategy, cross-functional alignment, market and competitive insights, and brand development. As the founder of RAS, Aditya leads initiatives in market research, competitive and regulatory intelligence, always guided by a commitment to rigor, contextual sensitivity, and collaborative problem-solving.
The Pop in Your Job
Driven by a vision to transform illness from a life-altering burden to a manageable inconvenience, Aditya is passionate about shaping healthcare solutions that improve lives and strengthen global health systems.